[Clinical application of CT-guided percutaneous targeted argon-helium cryoablation for soft tissue sarcoma].
OBJECTIVE
To evaluate the clinical efficacy of percutaneous targeted argon-helium cryoablation for soft tissue sarcoma and analyze the changes in CT findings and side effects in relation to the treatment.


METHODS
Thirty-two patients with soft tissue sarcoma were treated with CT-guided argon-helium cryoablation.


RESULTS
Three months after the treatment, 52 tumors showed obvious reduction in size with a total complete and partial remission rate of 73.1%. Postoperative CT scanning displayed low-density local necrosis in the tumors after cryotherapy, and consolidation of the lesions was observed at 3 months and lesion disappearance at 1 year after the therapy. The complications included pneumothorax, coughing, hemoptysis, fever, and slight elevation of aminotransferase.


CONCLUSIONS
CT-guided percutaneous targeted argon-helium cryoablation is safe and effective for lung cancer with minimal invasions.
Song
Qian
Q
Department of Oncology, 401 Hospital of PLA, Qingdao 266071, China.
Zhan
Ying
Y
Li
Lu-jia
LJ
D000328:Adult; D000368:Aged; D001128:Argon; D003452:Cryosurgery / Q000379:methods*; D005121:Extremities; D005260:Female; D006371:Helium; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery; D008175:Lung Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015641:Radiography, Interventional; D012509:Sarcoma / Q000601:surgery*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D006371:Helium; D001128:Argon